2024
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.
O'Donnell P, Hoimes C, Rosenberg J, Petrylak D, Mar N, Barata P, Srinivas S, Gourdin T, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Bowman I, Brancato S, Mildiner-Earley S, Zhu Y, Flaig T. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H. Journal Of Clinical Oncology 2024, 42: 4564-4564. DOI: 10.1200/jco.2024.42.16_suppl.4564.Peer-Reviewed Original ResearchPathological complete responsePathologic complete response ratePathological downstaging ratePathological downstagingEnfortumab vedotinEV treatmentUrothelial cancerPelvic lymph node dissectionAntitumor activityCisplatin-ineligible patientsNeoadjuvant treatment optionsPhase 1b/2 studyCentral pathology reviewMetastatic urothelial cancerLymph node dissectionEvent-free survivalCancer-related therapyAntibody-drug conjugatesStage cT2Improved OSComplete responseECOG PSNeoadjuvant treatmentCisplatin-ineligibleNode dissection
2017
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
Fong L, Small E, Petrylak D, Quinn D, Antonarakis E, Kibel A, Chang N, Kandadi H, Sheikh N, Drake C. Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). Journal Of Clinical Oncology 2017, 35: 143-143. DOI: 10.1200/jco.2017.35.6_suppl.143.Peer-Reviewed Original ResearchMetastatic castration-resistant PCProstatic acid phosphataseProstate cancerIgG responsesDisease courseSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerAntigen-presenting cell activationCastration-resistant prostate cancerPeripheral blood mononuclear cellsAndrogen-dependent prostate cancerBlood mononuclear cellsCross-trial comparisonsCancer-related antigensGranulocyte-macrophage colony-stimulating factorMacrophage colony-stimulating factorColony-stimulating factorImproved OSAndrogen suppressionClinical benefitAutologous immunotherapyDisease stageMononuclear cellsAntibody responseClinical trials